Evaxion A/S announced on May 22, 2025, that the first patient has been dosed in the one-year extension of its ongoing Phase 2 trial for EVX-01. EVX-01 is a personalized cancer vaccine designed with the company’s AI-Immunology platform for advanced melanoma.
This extension phase will involve patients receiving additional EVX-01 doses as monotherapy, after completing two years of combination therapy with an anti-PD-1 agent. The objective is to assess the independent effects of EVX-01 and its potential as a standalone treatment option.
The trial extension is expected to incur minimal costs, as the trial sites are already running and the vaccine product has been produced. This strategic move aims to explore EVX-01’s full potential beyond its combination use with checkpoint inhibitors, offering a meaningful option for patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.